KLK3 and melanoma: Published studies have explored the combination of single or dual CTLA4/PD-1 inhibitors and MYB oncoprotein targeting DNA vaccines (53), SSX2 cancer antigen (54), PSMA prostate-specific antigen (55), and TRP-2 and gp100 melanoma-specific antigens (56).